Infigratinib NEW

Product Name：NVP-BGJ398 Infigratinib Powder

CAS Number：872511-34-7

Chemical Name：3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea

Infigratinib, also known as NVP-BGJ398, is a small-molecule tyrosine kinase inhibitor renowned for its high selectivity and potency against Fibroblast Growth Factor Receptors (FGFRs), including FGFR1, FGFR2, and FGFR3. This powder form serves as the active pharmaceutical ingredient (API) for the development of anti-cancer drugs. By specifically blocking the FGFR signaling pathway, Infigratinib effectively inhibits tumor cell proliferation, angiogenesis, and metastasis.

Key Features:

• Mechanism of Action: Selectively targets FGFR kinases, disrupting oncogenic signaling in tumor cells.

• Purity: Manufactured to meet stringent pharmaceutical standards, ensuring high purity (≥99.5%) with tightly controlled impurity levels.

Indications:

• Approved for the treatment of unresectable, locally advanced, or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

• Under clinical investigation for additional FGFR-driven malignancies, such as urothelial cancer and certain breast cancers.

Storage and Handling:

• Store refrigerated at 2 - 8°C in a tightly sealed, light-resistant container.

• Protect from moisture and light to maintain chemical stability.

• Handle with appropriate personal protective equipment to avoid direct contact.

Whether for drug development, pre-clinical research, or commercial pharmaceutical manufacturing, NVP-BGJ398 Infigratinib Powder offers a reliable and effective solution for targeting FGFR-related cancers.